Loading clinical trials...
Loading clinical trials...
Study on the Efficacy and Safety of JSKN016 Combined With Toripalimab and Carboplatin as Neoadjuvant Therapy in Resectable Stage II-III Non-small Cell Lung Cancer Patients
Conditions
Interventions
JSKN016 + Toripalimab + Carboplatin
Locations
1
China
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, China
Start Date
March 1, 2026
Primary Completion Date
January 1, 2027
Completion Date
January 1, 2029
Last Updated
March 27, 2026
NCT07410975
NCT06945484
NCT03620669
NCT04027647
NCT05816499
NCT07150598
Lead Sponsor
Shanghai Pulmonary Hospital, Shanghai, China
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions